4D Molecular Therapeutics, Inc.

NasdaqGS:FDMT Stok Raporu

Piyasa değeri: US$360.1m

4D Molecular Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

4D Molecular Therapeutics CEO'su David Kirn, Sep2013 tarihinde atandı, in görev süresi 11.17 yıldır. in toplam yıllık tazminatı $ 10.29M olup, şirket hissesi ve opsiyonları dahil olmak üzere 5.8% maaş ve 94.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 3.59% ine doğrudan sahiptir ve bu hisseler $ 12.92M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.1 yıl ve 4 yıldır.

Anahtar bilgiler

David Kirn

İcra Kurulu Başkanı

US$10.3m

Toplam tazminat

CEO maaş yüzdesi5.8%
CEO görev süresi11.2yrs
CEO sahipliği3.6%
Yönetim ortalama görev süresi3.1yrs
Yönetim Kurulu ortalama görev süresi4yrs

Son yönetim güncellemeleri

Recent updates

Companies Like 4D Molecular Therapeutics (NASDAQ:FDMT) Are In A Position To Invest In Growth

Nov 24
Companies Like 4D Molecular Therapeutics (NASDAQ:FDMT) Are In A Position To Invest In Growth

4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure

Oct 04

4D Molecular Therapeutics (NASDAQ:FDMT) Is In A Good Position To Deliver On Growth Plans

Aug 10
4D Molecular Therapeutics (NASDAQ:FDMT) Is In A Good Position To Deliver On Growth Plans

4D Molecular Therapeutics: R100 Vector Pushes Forward To Bring Q4 Of 2024 DME Data

Jul 19

4D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution

Apr 29

4D Molecular Therapeutics Advances Wet AMD Treatment Paradigm

Feb 06

4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024

Jan 25

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates

Nov 12
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates

We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

Nov 08
We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation

May 08
Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation

We're Keeping An Eye On 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

Sep 29
We're Keeping An Eye On 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

4D Molecular Therapeutics GAAP EPS of -$0.87, revenue of $0.16M

Aug 11

Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation

Jun 11
Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation

CEO Tazminat Analizi

David Kirn'un ücretlendirmesi 4D Molecular Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$143m

Jun 30 2024n/an/a

-US$110m

Mar 31 2024n/an/a

-US$105m

Dec 31 2023US$10mUS$597k

-US$101m

Sep 30 2023n/an/a

-US$96m

Jun 30 2023n/an/a

-US$111m

Mar 31 2023n/an/a

-US$110m

Dec 31 2022US$3mUS$586k

-US$107m

Sep 30 2022n/an/a

-US$105m

Jun 30 2022n/an/a

-US$102m

Mar 31 2022n/an/a

-US$81m

Dec 31 2021US$5mUS$570k

-US$71m

Sep 30 2021n/an/a

-US$67m

Jun 30 2021n/an/a

-US$52m

Mar 31 2021n/an/a

-US$60m

Dec 31 2020US$702kUS$451k

-US$57m

Sep 30 2020n/an/a

-US$52m

Jun 30 2020n/an/a

-US$61m

Mar 31 2020n/an/a

-US$54m

Dec 31 2019US$554kUS$430k

-US$49m

Sep 30 2019n/an/a

-US$35m

Jun 30 2019n/an/a

-US$21m

Mar 31 2019n/an/a

-US$15m

Dec 31 2018US$546kUS$396k

-US$10m

Tazminat ve Piyasa: David 'nin toplam tazminatı ($USD 10.29M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 2.14M ).

Tazminat ve Kazançlar: David şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.


CEO

David Kirn (61 yo)

11.2yrs

Görev süresi

US$10,286,808

Tazminat

Dr. David H. Kirn, M.D., serves as Director at Coagulant Therapeutics, Inc He co-founded 4D Molecular Therapeutics, Inc. in 2013 and has been its Chief Executive Officer since September 12, 2013. Dr. Kirn...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
John Milligan
Executive Chairman4.3yrsUS$581.44k0.22%
$ 779.0k
David Kirn
Co-Founder11.2yrsUS$10.29m3.59%
$ 12.9m
Fariborz Kamal
President & COO4.8yrsUS$4.54m0.013%
$ 46.3k
Noriyuki Kasahara
Chief Scientific Officerless than a yearUS$488.91kVeri yok
Robert Kim
Chief Medical Officer2.1yrsUS$3.96m0.0023%
$ 8.1k
Theresa Janke
Co-Founder & Chief of Staff11.8yrsUS$2.70mVeri yok
Uneek Mehra
Chief Financial & Business Officer1.2yrsVeri yokVeri yok
Scott Bizily
Chief Legal Officer & Corporate Secretary3.2yrsVeri yok0.015%
$ 52.8k
An Song
Chief Development Officer3yrsVeri yokVeri yok
Alan Cohen
Senior VP & Therapeutic Area Head of Pulmonologyno dataVeri yokVeri yok
Christopher Simms
Chief Commercial Officerless than a yearVeri yokVeri yok
Karen Carothers
Controller8.3yrsVeri yokVeri yok

3.1yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim: FDMT 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.1 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
John Milligan
Executive Chairman4.3yrsUS$581.44k0.22%
$ 779.0k
David Kirn
Co-Founder11.2yrsUS$10.29m3.59%
$ 12.9m
Charles Theuer
Independent Director8.9yrsUS$352.62k0.070%
$ 252.0k
Susannah Gray
Independent Director4.3yrsUS$352.62k0%
$ 0
Paul Utz
Member of Scientific Advisory Boardless than a yearVeri yokVeri yok
Richard Moss
Member of Scientific Advisory Boardless than a yearVeri yokVeri yok
Jacob Chacko
Independent Director5.7yrsUS$352.62k0%
$ 0
Shawn Tomasello
Independent Director4yrsUS$345.12k0%
$ 0
Daniel Takefman
Member of Scientific Advisory Boardless than a yearVeri yokVeri yok
Amit Gaggar
Member of Scientific Advisory Boardless than a yearVeri yokVeri yok
Nancy Miller-Rich
Independent Director4yrsUS$340.12k0%
$ 0
Arshad Khanani
Chair of Ophthalmology Advisory Boardless than a yearVeri yokVeri yok

4.0yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: FDMT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4 yıldır).